Radioiodine therapy for hyperthyroidism

New England Journal of Medicine

Volumn 364, Issue 6, 2011, Pages 542-550

  Ross, Douglas S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID; LEVOTHYROXINE; LIOTHYRONINE; NONSTEROID ANTIINFLAMMATORY AGENT; SODIUM IODIDE I 131; THIAMAZOLE; THYROXINE;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; COLON CANCER; CORTICOSTEROID THERAPY; COST OF ILLNESS; DRUG COST; FEMALE; FREE THYROXINE INDEX; GRAVES DISEASE; HEART PALPITATION; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION SAFETY; RADIATION THYROIDITIS; REVIEW; SINGLE DRUG DOSE; THYROID CANCER; THYROIDITIS; THYROTOXICOSIS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TREMOR;

EID: 79851500082     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct1007101     Document Type: Review

References (48)

1. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997;26:189-218. (Pubitemid 27123901)
2. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-99.
3. Tibaldi JM, Barzel US, Albin J, Surks M. Thyrotoxicosis in the very old. Am J Med 1986;81:619-22. (Pubitemid 17178140)
4. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991;229:415-20.
5. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-9. (Pubitemid 32164903)
6. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis: thyroid storm. Endocrinol Metab Clin North Am 1993;22:263-77. (Pubitemid 23187800)
7. Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994;4:319-26. (Pubitemid 24295429)
8. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010;31:139-70.
9. Silva JE, Bianco SDC. Thyroid-adrenergic interactions: physiological and clinical implications. Thyroid 2008;18:157-65. (Pubitemid 351271529)
10. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P. Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab 1988;67: 656-62.
11. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38.
12. Parma J, Duprez L, Van Sande J, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997; 82:2695-701. (Pubitemid 27337896)
13. Dobyns BM, Vickery AL, Maloof F, Chapman EM. Functional and histoloic effects of therapeutic doses of radioactive iodine on the thyroid of man. J Clin Endocrinol Metab 1953;13:548-67.
14. Törring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine - a prospective, randomized study. J Clin Endocrinol Metab 1996;81:2986-93. (Pubitemid 26323897)
15. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;326:1733-8.
16. Ljunggren JG, Törring O, Wallin G, et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998;8:653-9. (Pubitemid 28405151)
17. Abraham-Nordling M, Törring O, Hamberger B, et al. Graves' disease: a longterm quality-of-life follow-up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005;15:1279-86. (Pubitemid 41821763)
18. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-17. (Pubitemid 40300299)
19. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129-35.
20. Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioiodine in treating young Graves' patients. J Clin Endocrinol Metab 2004;89:4229-33. (Pubitemid 39244416)
21. Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009; 94:3700-7.
22. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338: 73-8. (Pubitemid 28042269)
23. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321:1349-52. (Pubitemid 19284190)
24. Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodineassociated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010;95:1333-7.
25. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radio-iodine treatment: systemic review and meta-analysis of randomised control trials. BMJ 2007;334:514.
26. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduced the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;83:685-7. (Pubitemid 28496558)
27. Kubota S, Ohye H, Yano G, et al. Two-day thionamide withdrawal prior to radio-iodine uptake sufficiently increases uptake and does not exacerbate hyperthy-roidism compared to 7-day withdrawal in Graves' disease. Endocr J 2006;53:603-7. (Pubitemid 44691010)
28. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity: results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995;25:186-93.
29. Jarløv AE, Hegedüs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) 1995;43:325-9.
30. Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid 2005;15: 1321-31. (Pubitemid 43132677)
31. Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Am J Med 1995;99:173-9.
32. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87:1073-7.
33. 131I therapy for Graves' disease. N Engl J Med 1984;311:426-32.
34. Ross DS, Ridgway EC, Daniels GH. Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. Ann Intern Med 1984;101:488-90. (Pubitemid 14018044)
35. Goldstein R, Hart IR. Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med 1983;309:1473-6. (Pubitemid 14211570)
36. Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf) 1999;50:197-202. (Pubitemid 29100006)
37. Nygaard B, Hegedüs L, Ulriksen P, Nielson KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999;159:1364-8. (Pubitemid 29293600)
38. Holm LE, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med 1982; 23:103-7. (Pubitemid 12166906)
39. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine- 131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf) 2005;62:331-5. (Pubitemid 40380414)
40. Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML. Evidencebased management of toxic multinodular goiter (Plummer's disease). World J Surg 2008;32:1278-84.
41. In H, Pearce E, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves disease: a cost-effectiveness analysis. J Am Coll Surg 2009; 209:170-9.
42. Nygaard B, Faber J, Veje A, Hegedüs L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid 1999;9: 477-81. (Pubitemid 29244925)
43. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998;280: 347-55. (Pubitemid 28503219)
44. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1999; 353:2111-5. (Pubitemid 29278480)
45. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007;109:1972-9. [Erratum, Cancer 2007;110:1875.]
46. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998;338:712-8. (Pubitemid 28115089)
47. Nuclear Regulatory Commission. Precautions to protect children who may come into contact with patients released after therapeutic administration of iodine-131. NRC regulatory issues summary 2008-11. (http://www.nyc.gov/html/doh/ downloads/pdf/radioh/radioh-nrc-regulatory-issuesummary.pdf.)
48. Siegel JA, Silberstein EB. A closer look at the latest NRC patient release guidance. J Nucl Med 2008;49:17N-20N.